Current position:News > News > Insights
HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours
吉满生物
2024-11-08
On 8 Nov., SystImmune, Inc. received notification from the US FDA that its Phase I clinical trial application for BL-M17D1 (ADC) for the treatment of patients with advanced solid tumours has been approved by the FDA.

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumorsimage.png

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.


At present, including the new FDA licence for BL-M17D1, the Company has a total of six projects that have been licensed by the FDA to conduct clinical research, and the other five are: BL-B01D1, BL-M07D1, SI-B001, BL-M05D1, BL-M11D1 clinical trials in the United States.

Learn more about our HER2 catalog.

Latest news
Insights
2025-11-05
Accelerating Development of FOLR1 Target to Advance Multidimensional Cancer Therapy
Folate receptor alpha (FRα, FOLR1) is rapidly becoming one of the hottest targets in tumor therapy. With multiple antibody–drug conjugates (ADCs) now entering Phase III trials from global leaders like Eli Lilly and AstraZeneca, and emerging players such as Bio Thera and ProTarget Bio joining the race, competition around this target is intensifying.

From Elahere’s FDA approval to a new generation of FRα-directed ADCs, monoclonal antibodies, CAR-T therapies, and vaccines, the field is shifting from concept validation to clinical reality.

Dive into the full analysis to see how FRα is redefining the landscape of epithelial tumor treatment — and why it’s drawing worldwide attention from oncology innovators.
Insights
2025-10-31
PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies
While PD-1 inhibitors have transformed cancer treatment, their limits are becoming clear — and a new wave of innovation is rising. Cytokine engineering and PD-1 × IL-2 fusion therapies are redefining how we think about precision immune activation.

As PD-1 inhibitors reach their limits, the next frontier lies in cytokine engineering. Both Roche and Innovent Biologics are pursuing the PD-1 × IL-2v fusion strategy — yet with fundamentally different design philosophies.
Insights
2025-10-23
TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy
The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.
Current position:News > News > Insights
classify
HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours
吉满生物
2024-11-08
On 8 Nov., SystImmune, Inc. received notification from the US FDA that its Phase I clinical trial application for BL-M17D1 (ADC) for the treatment of patients with advanced solid tumours has been approved by the FDA.

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumorsimage.png

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.


At present, including the new FDA licence for BL-M17D1, the Company has a total of six projects that have been licensed by the FDA to conduct clinical research, and the other five are: BL-B01D1, BL-M07D1, SI-B001, BL-M05D1, BL-M11D1 clinical trials in the United States.

Learn more about our HER2 catalog.

Message consultation
reset
submit
Message
Message consultation
reset
submit